MLTX - MoonLake earns new Outperform at RBC Capital Markets on lead drug
2025-03-18 11:18:34 ET
More on MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon
- MoonLake Immunotherapeutics reports Q4 results
- MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset
- Seeking Alpha’s Quant Rating on MoonLake Immunotherapeutics
- Historical earnings data for MoonLake Immunotherapeutics